Sedation of Morbidly Obese for Balloon Insertion (SedBaloon)
Primary Purpose
Morbid Obesity
Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Fentanyl
Ketamine
Sponsored by
About this trial
This is an interventional treatment trial for Morbid Obesity
Eligibility Criteria
Inclusion Criteria:
- morbid obese indicated for gastric balloon insertion
Exclusion Criteria:
- Refusal Hypersensitivity to any of the study drugs
Sites / Locations
- Mansoura university
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Fentanyl group
Ketamine group
Arm Description
Outcomes
Primary Outcome Measures
Propofol consumption (milligrams)
Dose of prpofol (mg/kg) required for sedation during gastric balloon insertion
Secondary Outcome Measures
Full Information
NCT ID
NCT03747094
First Posted
November 13, 2018
Last Updated
November 17, 2018
Sponsor
Mansoura University
1. Study Identification
Unique Protocol Identification Number
NCT03747094
Brief Title
Sedation of Morbidly Obese for Balloon Insertion
Acronym
SedBaloon
Official Title
Fentanyl Versus Ketamine Supplementation for Prpofol Anesthesia During Balloon Insertion in Morbidly Obese Patients
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2018 (Anticipated)
Primary Completion Date
March 20, 2019 (Anticipated)
Study Completion Date
April 15, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mansoura University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This prospective study will assess the value of different supplements to orpofol bases anesthesia in morbidly obes e patients scheduled for balloon insertion. Two common drugs will be added to propofol bases anesthesia;Ketamine or fentanyl. Effect on prpofol consumption, post-procedure recovery profile, and patient satisfaction will be the study objectives.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fentanyl group
Arm Type
Active Comparator
Arm Title
Ketamine group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Intervention Description
0.5 mic/kg fentanyl will be given immediately before the procedure
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
0.25 mg ketamine will be administered immediately before the procedure
Primary Outcome Measure Information:
Title
Propofol consumption (milligrams)
Description
Dose of prpofol (mg/kg) required for sedation during gastric balloon insertion
Time Frame
24 hours after the endoscopy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
morbid obese indicated for gastric balloon insertion
Exclusion Criteria:
- Refusal Hypersensitivity to any of the study drugs
Facility Information:
Facility Name
Mansoura university
City
Al Manşūrah
State/Province
Dkahleya
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Sedation of Morbidly Obese for Balloon Insertion
We'll reach out to this number within 24 hrs